Following the success of our past events, SMi’s third Biosimilars and Biobetters conference will build upon the progress made in previous meetings and further develop the ideas and strategies that were debated and discussed. In particular how industry players will face regulatory challenges in approval of follow on biologics, rising development costs, threat from competition and a similar if not bigger challenge to that seen in marketing of innovator drugs.

There will be case studies from those who are both developing and distributing follow on biologics. With analysis of key trends in biologic pipelines, methods in clinical trials for biosimilar approval, a review of emerging markets, assessment of biosimilar manufacturing, post approval strategy and future forecasting for follow on biologics.

SMi’s Biosimilars and Biobetters event will provide up to date information from key opinion leaders in the biologics industry with discussion and debate and opportunities for networking between CROs, CMOs, law firms, regulatory bodies, pharma and biotechs.

If you are interested in speaking at the conference, please contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it

For sponsorship and exhibition opportunities, please contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Why should you attend this event?

Hear keynote addresses from:

Laura McKinley, Director Worldwide Regulatory Strategy, Pfizer

Paul Greenland, EMEA Director of Biosimilars and Proprietary Marketing, Hospira

Andrew Rankin, Head of Clinical Development, Teva Pharmaceuticals

Our expert speaker line-up also includes:

Sreedhar Sagi, Risk Management Compliance Officer Biopharmaceuticals Development, Sandoz
Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals USA, Inc
Anne Dollard, Chief Patent Counsel, Deputy General Counsel, Takeda Pharmaceuticals
Sandy Eisen, Chief Medical Officer, former CMO, Frontline Pharma Consulting, Teva Pharmaceuticals
David Szymkowski, Senior Director, Research, Biotherapeutics, Xencor, Inc
Steve Brocchini, CSO, PolyTherics Ltd.
Nicola Travierso, General Manager, NTC SRL
Christopher Stothers, Partner, Arnold and Porter LLP
Peter Wittner, Senior Consultant, Interpharm Consultancy
Ori Hershkovitz, Partner and Head of Pharmaceutical Research, Sphera Global Healthcare Fund